˜_•¶ˆê——   ŒöŠJŒ”F23Œ

No. ”­•\˜_•¶“™‚Ì•W‘è–¼ ’˜ŽÒE‹¤’˜ŽÒ–¼ ŒfÚŽ–¼ o”Å”NŒŽ Šª(†):•Å DOI
1 Isoprene Side-chain of SMTP is Essential for Soluble Epoxide Hydrolase Inhibition and Cellular Localization.
Otake S, Ogawa N, Kitano Y, Hasumi K, Suzuki E.
Natural Product Communications
2016/02
11:223-228

2 Hypocholesterolemic effect of sesame oil (Kadoya Pure Sesame Oil)—a verification test with a randomized, double-blind, parallel-group, placebo-controlled study.
Seki K, Hasuike-Seo M, Kondo S, Ishikawa T, Suzuki E, Hasumi K.
Jpn Pharmacol Ther
2015/11
43:1473–1480

3 Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase.
Matsumoto N, Suzuki E, Tsujihara K, Nishimura Y, Hasumi K.
The Journal of Antibiotics
2015/11
68:685-690

4 Effects of intake of sesame oil (Kadoya Pure Sesame Oil) on the level of serum cholesterol in volunteers with slightly higher serum cholesterol—A randomized, double-blind, parallel-group, placebo-controlled study.
Seki K, Hasuike-Seo M, Kondo S, Sato N, Suzuki E, Hasumi K.
Jpn Pharmacol Ther
2015/06
43:687–696

5 Effects of orally administered pyrroloquinoline quinone disodium salt on dry skin conditions in mice and healthy female subjects.
Nakano M, Kamimura A, Watanabe F, Kamiya T, Watanabe D, Yamamoto E, Fukagawa M, Hasumi K, Suzuki E.
J Nutr Sci Vitaminol.
2015/06
61:241-246

6 Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer
Ito Y, Kikuchi E, Tanaka N, Kosaka T, Suzuki E, Mizuno M, Shinojima T, Miyajima A, Umezawa K, Oya M.
BMC Cancer
2015/04
15:324

7 Soluble Epoxide Hydrolase as an Anti-inflammatory Target of the Thrombolytic Stroke Drug SMTP-7
Matsumoto N, Suzuki E (joint first author), Ishikawa M, Shirafuji T, Hasumi K.
The Journal of Biological Chemistry
2014/10
289:35826-35838

8 Mechanism of the action of SMTP-7, a novel small-molecule modulator of plasminogen activation
Koyanagi K, Narasaki R, Yamamichi S, Suzuki E, Hasumi K.
Blood Coagulation and Fibrinolysis
2014/06
25(6):316-321

9 SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
Sawada H, Nishimura N, Suzuki E, Zhuang J, Hasegawa K, Takamatsu H, Honda K, Hasumi K.
J Cereb Blood Flow Metab.
2014/02
34(2):235-241

10 Enhancement of radiosensitivity by a unique novel NF-ƒÈB inhibitor, DHMEQ, in prostate cancer.
Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N, Oya M.
Br J Cancer
2012/06
107(4):652-657

11 Prognostic role of KiSS-1 and possibility of therapeutic modality of metastin, the final peptide of the KiSS-1 gene, in urothelial carcinoma.
Takeda T, Kikuchi E, Mikami S, Suzuki E, Matsumoto K, Miyajima A, Okada Y, Oya M.
Mol Cancer Ther.
2012/04
11(4):853-863

12 Pre-SMTP, a key precursor for the biosynthesis of the SMTP plasminogen modulators
Nishimura Y, Suzuki E, Hasegawa K, Nishimura N, Kitano Y, Hasumi K.
The Journal of Antibiotics
2012/04
65(9):483-485

13 Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M
Journal of Urology
2011/05
185(1): 2376-2381

14 Potent Cytotoxic effect of a novel Nuclear Factor-kappa B inhibitor on human bladder cancer cells producing various cytokines,
Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M,
Urology
2010/04
75(4):805-812

15 Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.
Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B.
Int J Oncol.
2010/03
36:1299-1307

16 Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo.
Kanai K, Kikuchi E, Mikami S, Suzuki E, Uchida Y, Kodaira K, Miyajima A, Ohigashi T, Nakashima J, Oya M.
Cancer Sci.
2010/01
101:216-223

17 Potent Cytotoxic Effect of a Novel Nuclear Factor-kappa B Inhibitor on Human Bladder Cancer Cells Producing Various Cytokines
Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
Urology
2010/01
75: 805-812

18 Preparation of conophylline affinity nano-beads and identification of a target protein.
Suzuki E, Ogura H, Kato K, Takei I, Kabe Y, Handa H, Umezawa K.
Bioorg Med Chem.
2009/08
17: 6188-6195

19 Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
Suzuki E, Sugiyama C, Umezawa K.
Biomed Pharmacother
2009/02
63:351-358

20 Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
Saitoh T, Suzuki E, Takasugi A, Obata R, Ishikawa Y, Umezawa K, Nishiyama S.
Bioorg Med Chem Lett.
2009/01
19: 5383-5386

21 Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E, Ninomiya Y, Umezawa K.
Biochem Biophys Res Commun
2009/01
379:379-383

22 Inhibition of NF-kB activation by penicillic acid and dihydropenicillic acid isolated from fungi
Tachibana M, Matsui C, Takeuchi Y, Suzuki E, Umezawa K.
Heterocycles
2008/07
76:1561-1569

23 Inhibition of macrophage activation and phagocytosis by a novel NF-kappa B inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E, Umezawa K.
Biomed Pharmacother.
2006/11
60:578-586